Published in

Wiley, Liver International, 5(37), p. 653-661, 2016

DOI: 10.1111/liv.13288

Links

Tools

Export citation

Search in Google Scholar

Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study

Journal article published in 2016 by Am M. Pellicelli, Roberto Villani, Valeria Pace Palitti, Pace Palitti, Pascal Vignally, F. Ceccherini-Silberstein, Massimo Siciliano, Valerio Giannelli, Alessandra Moretti, Pierluigi Tarquini, Gaetano Scifo, Vincenzo Messina, Antonio Ascione, Antonio Izzi, Massimo Marignani and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients.